NEW YORK, December 20, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Dyax Corp. (NASDAQ: DYAX), IPC The Hospitalist Company, Inc. (NASDAQ: IPCM), Array BioPharma Inc. (NASDAQ: ARRY), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), and Wright Medical Group, Inc. (NASDAQ: WMGI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Dyax Corp. Research Report
On December 9, 2013, Dyax Corp. (Dyax) announced positive results from both preclinical studies of the investigational product DX-2930 and its biomarker assay program for detection of contact system activation of plasma kallikrein (pKal) at American Society of Hematology Annual Meeting and Exposition on December 7-10, 2013. The Company stated that DX-2930 is currently being studied in a placebo-controlled, dose-escalation Phase 1 trial in healthy subjects, with results expected in Q1 2014. Burt Adelman, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Dyax, commented, "A key finding from ex-vivo experimental studies is the observation that DX-2930 and ecallantide can be compared as inhibitors of pKal. The successful development of ecallantide has clearly demonstrated that pKal is a valid target. We are leveraging this knowledge to develop DX-2930." The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
IPC The Hospitalist Company, Inc. Research Report
On December 12, 2013, IPC The Hospitalist Company, Inc. (IPC) announced that it has completed the acquisition of the assets of affiliated entities: Park Avenue Health Care Management, LLC; Park Avenue Medical Associates, PC; Park Avenue Medical Associates, LLC; and Geriatric Services, PC (collectively referred as Park Avenue). IPC stated that the acquisition represents a new market for the Company in New York metropolitan area, and an expansion of its existing operations in Connecticut and Massachusetts. Adam Singer, M.D., Chairman and CEO of IPC, stated, "Acquiring a practice of the size and quality of Park Avenue is a milestone for our company. This represents a new level of commitment to leadership in patient care in the post-acute setting, as we continue to execute on our mission of delivering excellent quality of care in each type of inpatient care facility across the care continuum. Park Avenue is one of the most highly developed teams of post-acute care specialists in the country, and we prize the intellectual capital they bring to our organization." The Full Research Report on IPC The Hospitalist Company, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Array BioPharma Inc. Research Report
On December 9, 2013, Array BioPharma Inc. (Array BioPharma) announced positive data for filanesib (ARRY-520) as a single agent and in combination with proteasome inhibitors in patients with multiple myeloma at the 2013 Annual Meeting of the American Society of Hematology. Michael Needle, MD, Chief Medical Officer of Array BioPharma, stated, "Multiple myeloma remains an incurable disease, with a significant unmet medical need in patients who are relapsed/refractory to IMiDs and proteasome inhibitors. Filanesib is a first-in class drug in myeloma that is well tolerated and has shown very encouraging clinical activity in heavily pretreated patients who have limited therapeutic options. Furthermore, we are excited about the potential of our patient selection marker, AAG, which should help us identify which patients have the best chance to benefit from receiving filanesib." The Full Research Report on Array BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Lexicon Pharmaceuticals, Inc. Research Report
On December 3, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). The Company informed that the primary endpoint of this study was the change in stool consistency averaged from baseline to day 28. Pablo Lapuerta, M.D., Chief Medical Officer of Lexicon Pharmaceuticals, stated, "While LX1033 showed similar improvements in stool consistency as compared to the placebo patients who completed the study, there were positive effects on abdominal pain in the treated group that warrant further study. While this initial Phase 2a study was underway, we completed long-term toxicology studies that would allow us to conduct a Phase 2b study at doses informed by the current results and with a duration of 12 weeks, a treatment period that has historically been important to identify clinically meaningful changes as compared to placebo." The Full Research Report on Lexicon Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Wright Medical Group, Inc. Research Report
On December 16, 2013, Wright Medical Group, Inc. (Wright Medical) reported that MicroPort Scientific Corporation (MicroPort) advised the Company that the Hong Kong Stock Exchange has granted clearance of the disclosure circular required with respect to its shareholder meeting to approve the acquisition of the Wright's OrthoRecon business. The Company added that MicroPort has scheduled a shareholder meeting to approve the transaction on January 3, 2014. Wright Medical stated that it expects the transaction to be closed on or about January 9, 2014. Wright Medical added that after closing of the transaction, it plans to provide further details of the financial impacts of the transaction, as well as 2014 financial guidance in its Q4 2013 conference call, scheduled for February 24, 2014. The Full Research Report on Wright Medical Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved